Merck cites EnWave''s REV? Technology as a Faster, Viable Drying Alternative to Vial-Based Lyophilization for Vaccines and Biologics
(PresseBox) - EnWave Corporation (TSX-V:ENW | FSE:E4U) (?EnWave?, or the ?Company? https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/)& Co. Inc (?Merck?) published a research paper citing Mechanism for Faster Drying Times Achieved with Microwave? was published in the January 19, 2021 edition of PharmSciTech, the official journal of the American Association of Pharmaceutical Scientists.
Merck?s nine-month evaluation used a lab-scale freezeREV
The authors of the research article note that both the global pandemic and the rapid spread of COVID-19 have emphasised the need for accelerated vaccine development and on-demand, flexible manufacturing options. The published evaluation results stated that ?Microwave vacuum drying serves as a faster alternative to freeze drying of biologically active materials such as vaccines, proteins, and microorganism cultures?. Data from the study shows that EnWave?s freezeREV
Merck has been an EnWave research partner since 2015.
EnWave plans to continue collaborating with GEA Lyophil through a Joint Development Agreement to further refine its freezeREV
The full research article can be found atSpringer Link.
About EnWave
EnWave Corporation, a Vancouver-based advanced technology company, has developed a Radiant Energy Vacuum (?REV??) ? an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV? technology, shortening the time from harvest to high-quality, marketable cannabis products.
REV? technology?s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave?s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV? technology. The company has signed over forty royalty-bearing licenses to date in twenty countries world-wide. In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, LLC, to manufacture, market and sell all-natural dairy snack products in the United States, including the Moon Cheese
EnWave has introduced REV? as a disruptive dehydration platform in the food and cannabis sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently offers two distinct commercial REV? platforms:
nutraREV
quantaREV
More information about EnWave is available at www.enwave.net.
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management''s expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company''s strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing, are forward-looking statements. All third-party claims referred to in this release are not guaranteed to be accurate. All third-party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.01.2021 - 09:50 Uhr
Sprache: Deutsch
News-ID 1564126
Anzahl Zeichen: 6079
contact information:
Contact person:
Town:
Vancouver, B.C.
Phone:
Kategorie:
Internet
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 478 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Merck cites EnWave''s REV? Technology as a Faster, Viable Drying Alternative to Vial-Based Lyophilization for Vaccines and Biologics
"
steht unter der journalistisch-redaktionellen Verantwortung von
Swiss Resource Capital AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
